Methods and Compositions for Modulating Apolipoprotein (A) Expression
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application PCT/US2013/042532, filed May 23, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,574,193 | Methods and Compositions for Modulating Apolipoprotein (A) Expression In force · Medium confidence UsedRemaining | Ionis Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 9,884,072 | Methods and Compositions for Modulating Apolipoprotein (A) Expression In force · Medium confidence | Ionis Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 10,174,318 | Antisense Oligonucleotide Compositions In force · High confidence | Ionis Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,478,448 | Methods and Compositions for Modulating Apolipoprotein (A) Expression In force · Low confidence | Ionis Pharmaceuticals, Inc. | In force | Low confidence | ||
| US 11,859,180 | Antisense Oligonucleotide Compositions In force · High confidence | Ionis Pharmaceuticals, Inc. | In force | High confidence | ||
| US 9,885,045 | Methods and Compositions for Modulating Apolipoprotein (A) Expression In force · High confidence | Ionis Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,472,629 | Methods and Compositions for Modlating Apolipoprotein (A) Expression In force · High confidence | Ionis Pharmaceuticals, Inc. | In force | High confidence | ||
| US 11,634,711 | Methods and Compositions for Modulating Apolipoprotein (A) Expression In force · Low confidence | Ionis Pharmaceuticals, Inc. | In force | Low confidence | ||
| Application 14/401,761 | Antisense Oligonucleotide Compositions Abandoned Abandoned Oct 18, 2016 | Ionis Pharmaceuticals, Inc. | Abandoned | Abandoned Oct 18, 2016 | ||
| Application 14/403,557 | Methods and Compositions for Modulating Apolipoprotein (A) Expression Abandoned Abandoned Nov 3, 2016 | Ionis Pharmaceuticals, Inc. | Abandoned | Abandoned Nov 3, 2016 | ||
| 5 more records in this group · Pro | ||||||
10 of 15 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 15.
8 of these are in force and held by Ionis Pharmaceuticals, Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.